The Zhitong Finance App learned that Pfizer (PFE.US) and Bristol-Myers Squibb (BMY.US) announced that starting September 8, patients can directly purchase their jointly developed anticoagulant drug Eliquis for $346 a month in cash through the newly launched “Eliquis 360 Support” platform. This price is 40% lower than the price of conventional drugs in the US market, but it is still higher than the 2026 health insurance price determined by the Biden administration through the “Inflation Reduction Act” negotiations last year — at which time, medical insurance patients' monthly out-of-pocket expenses will drop to $231.

The Zhitong Finance App learned that Pfizer (PFE.US) and Bristol-Myers Squibb (BMY.US) announced that starting September 8, patients can directly purchase their jointly developed anticoagulant drug Eliquis for $346 a month in cash through the newly launched “Eliquis 360 Support” platform. This price is 40% lower than the price of conventional drugs in the US market, but it is still higher than the 2026 health insurance price determined by the Biden administration through the “Inflation Reduction Act” negotiations last year — at which time, medical insurance patients' monthly out-of-pocket expenses will drop to $231.